ARCHIVES

Erbitux Plus Chemo Effective For NSCLC; Carboplatin Prevents Testicular Recurrence

This article is from The Cancer Letter archive.

Vol. 31 No. 7 | July 25, 2008

Download PDF Visit The Full Archive

Related Articles

Adding Aresenic To Therapy Improves APL Survival

July 27, 2007

DOD To Reimburse Care On Clinical Trials In Three-Year Deal

February 9, 1996

NCI Get Go-Ahead For New Cancer Control Projects Totaling $7.4 Million, Funded By Grants, Contracts

October 21, 1977

Ungerleider To Leave NCI For Theradex Corp.

November 24, 2000

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

January 27, 1989

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000